In vivo biodistribution of I-131 labeled bleomycin (BLM) and isomers (A2 and B2) on experimental animal models

Avcibasi U., Demiroglu H., ÜNAK P. , Muftuler F. Z. B. , İÇHEDEF Ç. , Gumuser F. G.

JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, vol.285, no.2, pp.207-214, 2010 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 285 Issue: 2
  • Publication Date: 2010
  • Doi Number: 10.1007/s10967-010-0565-x
  • Page Numbers: pp.207-214


Bleomycins (BLMs; BLM, A2, and B2) were labeled with I-131 and radiopharmaceutical potentials were investigated using animal models in this study. Quality control procedures were carried out using thin layer radiochromatography (TLRC), high performance liquid chromatography (HPLC), and liquid chromatography (LC/MS/MS). Labeling yields of radiolabeled BLMs were found to be 90, 68, and 71%, respectively. HPLC chromatograms were taken for BLM and cold iodinated BLM (I-127-BLM). Five peaks were detected for BLM and three peaks for I-127-BLM in the HPLC studies. Two peaks belong to isomers of BLM. The isomers of BLM were purified with using HPLC. Biological activity of BLM was determined on male Albino Wistar rats by biodistribution and scintigraphic studies were performed for BLMs by using New Zelland rabbits. The biodistribution results of I-131-BLM showed high uptake in the stomach, the bladder, the prostate, the testicle, and the spinal cord in rats. Scintigraphic results on rabbits agrees with that of biodistributional studies on rats. The scintigraphy of radiolabeled isomers (I-131-A2 and I-131-B2) are similiarly found with that of I-131-BLM.